Huge congrats to @Mykalt45, co-founder and CEO of CrossBridge Bio, acquired by Eli Lilly for up to $300M.💛 • dual-payload ADC chemistry from UTHealth Houston • $10M seed • $15M CPRIT grant • Best Drug Developer, 2025 World ADC Awards • Eli Lilly deal Michael is a relentless founder, passionate about solving real problems. He doesn't just talk about them. He builds companies around them. He also leads @vitarnabio (ArtanBIO), a @vitadao-backed gene therapy program going after premature termination codons in aging. PTCs are early stop signals in the ribosome. Cell makes a broken protein, damage stacks up over a lifetime. His postdoc was on exactly this mechanism, in cystic fibrosis, where PTCs are the germline cause of disease. VITARNA is the somatic version, applied to aging. DeSci needs more builders like Michael. People who don't stop at one thesis, one company, or one disease.